BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route

Lagranderie, M.; Ravisse, P.; Marchal, G; Gheorghiu, M; Balasubramanian, V.; Weigeshaus, E.H.; Smith, Donald W.

doi:10.1016/0962-8479(93)90067-8

Cited by 68 publications

(43 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…or s.c. routes. Further studies in mice (27) and in guinea pigs (19,20) suggested that aerogenic BCG immunization imparted more protection than peripheral s.c. immunization. In adoptive transfer experiments, however, Orme and Collins (25) demonstrated that aerogenic immunization with BCG offered no protective advantage over s.c. immunization in mice.…”

Section: Discussionmentioning

confidence: 99%

Lymphocyte Recruitment and Protective Efficacy against Pulmonary Mycobacterial Infection Are Independent of the Route of PriorMycobacterium bovisBCG Immunization

et al. 2002

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Lymphocyte Recruitment and Protective Efficacy against Pulmonary Mycobacterial Infection Are Independent of the Route of PriorMycobacterium bovisBCG Immunization

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Since TB is primarily a respiratory airway infectious disease, it is believed that mucosal vaccination directed to the respiratory system may provide the best protection against pulmonary TB (5). While respiratory mucosal TB vaccination has previously been explored by delivering aerosolized BCG, conflicting results were reported (17,21,24,26,28), and it is unlikely that aerosol delivery of BCG will eventually become a mode of BCG vaccination for humans. In this regard, i.n.…”

mentioning

confidence: 93%

Single Intranasal MucosalMycobacterium bovisBCG Vaccination Confers Improved Protection Compared to Subcutaneous Vaccination against Pulmonary Tuberculosis

et al. 2004

View full text Add to dashboard Cite

Whether the intranasal (i.n.) route of Mycobacterium bovis BCG vaccination provides better protection against pulmonary tuberculosis than subcutaneous (s.c.) vaccination remains an incompletely solved issue. In the present study, we compared both immune responses and protection elicited by single BCG vaccinations via the i.n. or s.c. route in BALB/c mice. While both i.n. and s.c. vaccination triggered comparable levels of primary immune activation in the spleen and draining lymph nodes, i.n. vaccination led to a greater antigen-specific gamma interferon recall response in splenocytes than s.c. vaccination upon secondary respiratory mycobacterial challenge, accompanied by an increased frequency of antigen-specific lymphocytes. There was also a quicker cellular response in the lungs of i.n. vaccinated mice upon mycobacterial challenge. Mice vaccinated i.n. were found to be much better protected, particularly in the lung, than s.c. vaccinated counterparts against pulmonary tuberculosis at both 3 and 6 months postvaccination. These results suggest that the i.n. route of vaccination improves the protective effect of the current BCG vaccine.

show abstract

“…They are also a readily accessed mucosal site for the delivery of immunogens that might induce diverse mucosal immune responses. Pulmonary immunization strategies have been shown to generate potent Th1 responses and protective immunity against respiratory challenge with pathogens in several animal models (4,29,32,37,38).Because of the ease of generating vaccine constructs and the ability to administer repeated inoculations of the same vector, DNA immunization remains a promising vaccination strategy for eliciting cellular immune responses. Only a limited number of studies have been done to evaluate the immunogenicity of DNA vaccines following pulmonary delivery (4, 32).…”

mentioning

confidence: 99%

mentioning

confidence: 99%

Efficient Generation of Mucosal and Systemic Antigen-Specific CD8⁺T-Cell Responses following Pulmonary DNA Immunization

Bivas-Benita

Bar

Gillard

et al. 2010

J Virol

View full text Add to dashboard Cite

Although mucosal CD8؉ T-cell responses are important in combating mucosal infections, the generation of such immune responses by vaccination remains problematic. In the present study, we evaluated the ability of plasmid DNA to induce local and systemic antigen-specific CD8 ؉ T-cell responses after pulmonary administration. We show that the pulmonary delivery of plasmid DNA formulated with polyethyleneimine (PEI-DNA) induced robust systemic CD8 ؉ T-cell responses that were comparable in magnitude to those generated by intramuscular (i.m.) immunization. Most importantly, we observed that the pulmonary delivery of PEI-DNA elicited a 10-fold-greater antigen-specific CD8؉ T-cell response in lungs and draining lymph nodes of mice than that of i.m. immunization. The functional evaluation of these pulmonary CD8؉ T cells revealed that they produced type I cytokines, and pulmonary immunization with PEI-DNA induced lung-associated antigen-specific CD4 ؉ T cells that produced higher levels of interleukin-2 than those induced by i.m. immunization. Pulmonary PEI-DNA immunization also induced CD8 ؉ T-cell responses in the gut and vaginal mucosa. Finally, pulmonary, but not i.m., plasmid DNA vaccination protected mice from a lethal recombinant vaccinia virus challenge. These findings suggest that pulmonary PEI-DNA immunization might be a useful approach for immunizing against pulmonary pathogens and might also protect against infections initiated at other mucosal sites. Since establishing that antigen-specific CD8ϩ T-cell populations in mucosal sites may confer protection against intracellular pathogens that initiate infections at mucosal surfaces, vaccine strategies have been explored for eliciting cellular immune responses in mucosal tissues (40). Studies have been done to evaluate the immunogenicity of vaccines delivered to a variety of mucosal surfaces, including those of the nose, intestine, rectum, and vagina. These studies have shown that immunization at mucosal sites can induce larger numbers of antigen-specific CD8 ϩ T cells in mucosal tissues than parenteral immunization (3).Particular attention has focused on the lungs as a target for mucosal immunization. The lungs are an important mucosal portal of entry for pathogens. They are also a readily accessed mucosal site for the delivery of immunogens that might induce diverse mucosal immune responses. Pulmonary immunization strategies have been shown to generate potent Th1 responses and protective immunity against respiratory challenge with pathogens in several animal models (4,29,32,37,38).Because of the ease of generating vaccine constructs and the ability to administer repeated inoculations of the same vector, DNA immunization remains a promising vaccination strategy for eliciting cellular immune responses. Only a limited number of studies have been done to evaluate the immunogenicity of DNA vaccines following pulmonary delivery (4, 32). Although the importance of CD8 ϩ T lymphocytes in eradicating mucosal infections has been well established, it has not been determin...

show abstract

BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route

Cited by 68 publications

References 24 publications

Lymphocyte Recruitment and Protective Efficacy against Pulmonary Mycobacterial Infection Are Independent of the Route of PriorMycobacterium bovisBCG Immunization

Lymphocyte Recruitment and Protective Efficacy against Pulmonary Mycobacterial Infection Are Independent of the Route of PriorMycobacterium bovisBCG Immunization

Single Intranasal MucosalMycobacterium bovisBCG Vaccination Confers Improved Protection Compared to Subcutaneous Vaccination against Pulmonary Tuberculosis

Efficient Generation of Mucosal and Systemic Antigen-Specific CD8⁺T-Cell Responses following Pulmonary DNA Immunization

Contact Info

Product

Resources

About

BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route

Cited by 68 publications

References 24 publications

Lymphocyte Recruitment and Protective Efficacy against Pulmonary Mycobacterial Infection Are Independent of the Route of PriorMycobacterium bovisBCG Immunization

Lymphocyte Recruitment and Protective Efficacy against Pulmonary Mycobacterial Infection Are Independent of the Route of PriorMycobacterium bovisBCG Immunization

Single Intranasal MucosalMycobacterium bovisBCG Vaccination Confers Improved Protection Compared to Subcutaneous Vaccination against Pulmonary Tuberculosis

Efficient Generation of Mucosal and Systemic Antigen-Specific CD8+T-Cell Responses following Pulmonary DNA Immunization

Contact Info

Product

Resources

About

Efficient Generation of Mucosal and Systemic Antigen-Specific CD8⁺T-Cell Responses following Pulmonary DNA Immunization